Publicaciones en colaboración con investigadores/as de Princess Alexandra Hospital (7)

2021

  1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654

2018

  1. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

    New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2093-2104

2014

  1. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 12, pp. 1369-1378

2012

  1. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

2007

  1. 12-Month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

    Transplant International, Vol. 20, Núm. 1, pp. 27-36

2006

  1. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplantation recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

    Liver Transplantation, Vol. 12, Núm. 10, pp. 1464-1472

2004

  1. Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies

    American Journal of Transplantation, Vol. 4, Núm. 4, pp. 626-635